CSHL Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training Program

项目摘要 癌症基因发现和癌症生物学博士后研究培训计划的目标是 冷泉港实验室(CSHL)是为下一代癌症生物学家所追求的准备 将癌症基因发现与功能生物学相结合的独立研究事业，以促进 开发和应用新的癌症治疗、诊断和/或预防策略。 这个为期三年的研究培训计划的特点包括：必修课和选修课相结合 教学课程和研讨会；有组织的职业发展指导；毕业生和以社区为基础 教学选择；以及在我们指定的CSH、NCI指定的实验室中的研究经验 癌症中心。 癌症研究机会横跨高度集成的领域，包括：1)癌症遗传学-遗传学和 癌症的表观遗传进展；癌症诊断和实验技术发展 (CRISPR/Cas，单细胞分析)；2)癌症基因调控与细胞增殖-剪接，RNA 生物学，复制，核结构，转录，肿瘤生长和转移；3)癌症信号 转导-药物敏感性与耐药性、肿瘤微环境与转移、免疫反应； 4)数量生物学--群体遗传学、基因组结构和进化。 博士后实习生受益于：强大的教师与实习生比例；协作和多学科 研究环境；内部执行委员会，包括受训人员代表和 独立的外部咨询委员会；现场国际知名的科学会议和课程 计划；新扩建的最先进的癌症研究设施；增加对翻译的接触 肿瘤学是与诺斯韦尔健康公司新的机构伙伴关系的一部分。 在过去五年中，约有74名学员从该方案中受益，其中7人 受训人员(每年三名)得到NCI T32奖的支持，另外两名受训人员得到支持 由纽约州匹配和CSHL机构资助相结合。CSHL提交了一份竞争对手T32 2015年申请续签，要求提供四个职位，但未能获得续签NCI资金。 审查人员发现，该项目的总体影响很大，但也提到了几点和建议。全 在这次重新提交的报告中，对建议进行了仔细的评估和处理。计划增强功能 包括：为学员提供更多了解癌症临床影响的机会，并 了解进行和参与临床研究的复杂性；t32 学员具体活动，包括向公众传播科学的培训；以及获取知识 关于人群多样性在癌症健康差异研究中的重要性。选修课有 进行了更新，并采取了新的方法，以进一步加强方案申请者和参与者的多样性 已经开始了。

Project Summary The objective of the Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training Program at Cold Spring Harbor Laboratory (CSHL) is to prepare the next generation of cancer biologists to pursue independent research careers integrating cancer gene discovery with functional biology in order to facilitate the development and application of novel cancer therapeutic, diagnostic and/or preventive strategies. Features of this three-year research training program include: a combination of mandatory and elective didactic courses and seminars; structured career development guidance; graduate and community-based teaching options; and research experiences in laboratories integrated within our CSH, NCI designated Cancer Center. Cancer research opportunities span highly integrated areas that include; 1) Cancer Genetics - genetic and epigenetic progression of cancer; cancer diagnostics and experimental technology development (CRISPR/Cas, single cell analysis); 2) Cancer Gene Regulation and Cell Proliferation - splicing, RNA biology, replication, nuclear structure, transcription, tumor growth and metastasis; 3) Cancer Signal Transduction - drug sensitivity and resistance, tumor microenvironment and metastasis, immune response; and 4) Quantitative Biology- population genetics, genome structure and evolution. Postdoctoral trainees benefit from: a strong faculty to trainee ratio; a collaborative and multidisciplinary research environment; an internal Executive Committee that includes trainee representatives and an independent External Advisory Board; an on-site internationally renowned Scientific Meetings and Courses program; newly expanded state-of-the-art cancer research facilities; enhanced exposure to translational oncology as part of a new institutional partnership with Northwell Health. Over the past five years, approximately seventy-four trainees benefited from the program, of which seven trainees (three per year) were supported by the NCI T32 award, with two additional trainees being supported by combined New York State matching and CSHL institutional funding. CSHL submitted a competing T32 renewal application in 2015 requesting four positions that fell short of securing renewed NCI funding. Reviewers found the program's overall impact to be high, but noted several points and recommendations. All suggestions have been carefully evaluated and addressed in this resubmission. Program enhancements include: providing trainees with additional opportunities to understand the clinical impact of cancer and to gain an appreciation of the complexities involved in conducting and participating in clinical research; T32 trainee specific events that include training in Communicating Science to the Public; and gaining knowledge about the importance of population diversity in cancer health disparities research. Elective courses have been updated and new approaches to further enhance the diversity of program applicants and participants have begun.